TET2 anticorps (N-Term)
Aperçu rapide pour TET2 anticorps (N-Term) (ABIN1450172)
Antigène
Voir toutes TET2 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Réactivité croisée (Details)
- Species reactivity (tested):Human.
-
Purification
- Affinity chromatography purified via peptide column
-
Immunogène
- 18 amino acid synthetic peptide near the amino terminus of Human TET2
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))
-
Autre désignation
- TET2
-
Sujet
- TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14 % of patients with JAK2V617F-positive myeloproliferative neoplasms, and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.Synonyms: KIAA1546, Methylcytosine dioxygenase TET2
-
ID gène
- 54790
-
NCBI Accession
- NP_001120680
-
Pathways
- L'effet Warburg
Antigène
-